211 related articles for article (PubMed ID: 24155635)
1. Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.
Delea TE; Amdahl J; Chit A; Amonkar MM
Curr Oncol; 2013 Oct; 20(5):e371-87. PubMed ID: 24155635
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Fleeman N; Bagust A; Boland A; Dickson R; Dundar Y; Moonan M; Oyee J; Blundell M; Davis H; Armstrong A; Thorp N
Health Technol Assess; 2011; 15(42):1-93, iii-iv. PubMed ID: 22152751
[TBL] [Abstract][Full Text] [Related]
3. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer.
Delea TE; Hawkes C; Amonkar MM; Lykopoulos K; Johnston SR
Breast Care (Basel); 2013 Dec; 8(6):429-37. PubMed ID: 24550751
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Lipsitz M; Delea TE; Guo A
Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
[TBL] [Abstract][Full Text] [Related]
7. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of ribociclib plus letrozole
Buehler AM; Castilho G; Dionne PA; Stefani S
Ther Adv Med Oncol; 2021; 13():17588359211000593. PubMed ID: 33948121
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
Delea TE; Tappenden P; Sofrygin O; Browning D; Amonkar MM; Karnon J; Walker MD; Cameron D
Eur J Health Econ; 2012 Oct; 13(5):589-603. PubMed ID: 21701940
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.
Galve-Calvo E; González-Haba E; Gostkorzewicz J; Martínez I; Pérez-Mitru A
Clinicoecon Outcomes Res; 2018; 10():773-790. PubMed ID: 30532569
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
Stellato D; Thabane ME; Chandiwana D; Park J; Delea TE
Pharmacoeconomics; 2021 Jul; 39(7):853-867. PubMed ID: 34002341
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model.
Darvishi A; Daroudi R; Fazaeli AA
Health Econ Rev; 2023 Nov; 13(1):53. PubMed ID: 37943359
[TBL] [Abstract][Full Text] [Related]
15. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
16. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective.
Machado M; Einarson TR
Breast Cancer (Dove Med Press); 2012; 4():173-82. PubMed ID: 24367204
[TBL] [Abstract][Full Text] [Related]
18. Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Huang X; Weng X; Lin S; Liu Y; Luo S; Wang H; Ming WK; Huang P
BMJ Open; 2020 Aug; 10(8):e036107. PubMed ID: 32868353
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.
Bao Y; Zhang Z; He X; Cai L; Wang X; Li X
Curr Oncol; 2022 Aug; 29(9):6053-6067. PubMed ID: 36135045
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
